Monoclonal antibodies have proven to be a potent tool in our ability to prevent and treat SARS-CoV-2 infections. The current epidemic is driven in part by naturally occurring variants that elude ...

An innovative gene-editing strategy could establish a new way for the body to manufacture therapeutic proteins—including ...

Standing out from the crowd illustration. Businessman thinking twice about following the crowd over a cliff. Files included – jpg, ai (version 8 and CS3), svg, and eps (version 8) While common sense ...

Serum samples obtained from unvaccinated persons after infection with the B.1.1.7 (alpha), B.1.351 (beta), or B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ...

When children living with HIV are injected with neutralizing antibodies, the treatment can suppress cells that contain the virus and are capable of reactivating, an early-stage trial found. Details of ...

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for approximately 600 million documented cases of coronavirus disease 2019 (COVID-19), with almost 6.5 million deaths.

Researchers have developed a novel neutralizing agent, which becomes stronger as the coronavirus mutates. The emergence of unpredictable variants and their stronger infectivity make the COVID-19 ...

Neutralizing antibody levels against the original COVID-19 virus and omicron variants in vaccinated adults tend to decline by at least 15% per month after a single booster shot, a new study using ...

Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533 Vaccine-induced nAbs are detectable at much lower rates ...